This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International Croissance future

Future contrôle des critères 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Endo International.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.7%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Aug 16

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Jul 15

Endo International: Bankruptcy Seems Like The Only Practical Option

Jun 30

Endo International wins FDA approval for Micafungin new formulation

Jun 17

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

May 07

Radius Health partners with Endo unit for abaloparatide in Canada

Jan 05

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Endo International n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

OTCPK:ENDP.Q - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2023	2,012	-2,448	341	435	N/A
9/30/2023	2,070	-252	334	430	N/A
6/30/2023	2,160	-942	285	391	N/A
3/31/2023	2,182	-2,847	21	130	N/A
12/31/2022	2,319	-2,910	166	269	N/A
9/30/2022	2,552	-3,221	11	110	N/A
6/30/2022	2,783	-2,552	-9	80	N/A
3/31/2022	2,928	-681	277	369	N/A
12/31/2021	2,993	-569	326	411	N/A
9/30/2021	2,964	129	484	569	N/A
6/30/2021	2,827	109	345	429	N/A
3/31/2021	2,801	137	506	579	N/A
12/31/2020	2,903	247	327	402	N/A
9/30/2020	2,908	-102	195	268	N/A
6/30/2020	3,002	-75	299	378	N/A
3/31/2020	3,014	-190	180	251	N/A
12/31/2019	2,914	-361	30	98	N/A
9/30/2019	2,936	-418	108	190	N/A
6/30/2019	2,952	-522	63	135	N/A
3/31/2019	2,967	-477	47	128	N/A
12/31/2018	2,947	-962	177	267	N/A
9/30/2018	2,929	-968	238	329	N/A
6/30/2018	2,971	-921	324	434	N/A
3/31/2018	3,132	-1,565	311	435	N/A
12/31/2017	3,469	-1,233	428	554	N/A
9/30/2017	3,942	-4,294	N/A	507	N/A
6/30/2017	4,039	-4,386	N/A	309	N/A
3/31/2017	4,084	-3,300	N/A	742	N/A
12/31/2016	4,010	-3,224	N/A	528	N/A
9/30/2016	3,842	553	N/A	683	N/A
6/30/2016	3,704	-59	N/A	698	N/A
3/31/2016	3,518	-539	N/A	106	N/A
12/31/2015	3,269	-300	N/A	119	N/A
9/30/2015	2,858	-725	N/A	-75	N/A
6/30/2015	2,766	128	N/A	310	N/A
3/31/2015	2,624	260	N/A	492	N/A
12/31/2014	2,381	58	N/A	338	N/A
9/30/2014	2,303	-643	N/A	277	N/A
6/30/2014	2,310	-637	N/A	141	N/A
3/31/2014	2,429	-650	N/A	124	N/A
12/31/2013	2,125	189	N/A	299	N/A
9/30/2013	2,621	-628	N/A	711	N/A
6/30/2013	2,711	-629	N/A	683	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if ENDP.Q's forecast earnings growth is above the savings rate (2.4%).

Bénéfices vs marché: Insufficient data to determine if ENDP.Q's earnings are forecast to grow faster than the US market

Croissance élevée des bénéfices: Insufficient data to determine if ENDP.Q's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: Insufficient data to determine if ENDP.Q's revenue is forecast to grow faster than the US market.

Croissance élevée des revenus: Insufficient data to determine if ENDP.Q's revenue is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if ENDP.Q's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Endo International Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased to US$2.63

Price target decreased to US$6.17

Price target decreased to US$6.57

Consensus forecasts updated

Price target raised to US$7.45

Price target raised to US$6.91

Recent updates

Endo International plc to Report Q1, 2024 Results on May 30, 2024

Fourth Amended Reorganization Plan Filed by Endo International plc

Endo International plc to Report Q3, 2023 Results on Nov 06, 2023

Endo International plc, Annual General Meeting, Sep 07, 2023

Endo International plc Launches First Generic Version of Noxafil® (posaconazole) Injection

Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture

Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Two Affiliate Companies Joined Endo International plc Bankruptcy

Endo International plc Announces Asset Impairment Charges for Three Months Ended March 31, 2023

Endo International plc and SMSNA Launches App to Provide Peyronie's Disease Self-Assessment Tool

Nasdaq to Delist Common Stock of Endo International

Endo International Provides Delisting Update

Endo International plc(NasdaqGS:ENDP) dropped from NASDAQ Biotechnology Index

Endo International plc(NasdaqGS:ENDP) dropped from S&P TMI Index

Endo International plc Filed for Bankruptcy

Endo International plc Filed for Bankruptcy

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021)

Endo International sees 23% rise on 3x higher than normal volume

Endo outperforms defying bankruptcy fears and generic entry

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International Receives Non-Compliance Notice from Nasdaq

Endo International cools off, giving back some of its 85% Tuesday gain

Endo International plc(NasdaqGS:ENDP) dropped from S&P Pharmaceuticals Select Industry Index

Endo: Stick A Fork In It

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

Price target decreased to US$2.63

Endo International plc to Report Q1, 2022 Results on May 05, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to its Board of Directors

Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-To-Use Vials

Endo: About As Bad As It Gets

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo International plc Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

Price target decreased to US$6.17

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Investor sentiment deteriorated over the past week

Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.30 loss in 3Q 2020)

Investor sentiment improved over the past week

Endo: A Win In California But Equity Value Still A Question

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to US$6.57

Endo International: Loses Vasostrict Trial

Investor sentiment deteriorated over the past week

Endo International: Hires Restructuring Advisor

Consensus forecasts updated

Endo International: All About Ongoing Litigation

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.077 profit in 2Q 2020)

Investor sentiment improved over the past week

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Investor sentiment deteriorated over the past week

Endo International: Bankruptcy Seems Like The Only Practical Option

Endo International plc(NasdaqGS:ENDP) dropped from Russell 2500 Growth Index

Endo International wins FDA approval for Micafungin new formulation

Chairman Paul Campanelli has left the company

Senior Independent Director Roger Kimmel has left the company

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.69 in 1Q 2020)

Endo International plc Announces Asset Impairment Results for the First Quarter Ended March 31, 2021

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

Chairman exercised options and sold US$1.4m worth of stock

Investor sentiment deteriorated over the past week

Independent Director recently sold US$150k worth of stock

Investor sentiment deteriorated over the past week